Trevi Therapeutics, Inc. TRVI Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s change in accrued liabilities?
- Trevi Therapeutics, Inc. (TRVI) reported change in accrued liabilities of -$1.08M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Trevi Therapeutics, Inc.'s change in accrued liabilities increased by 28.4% year-over-year, from -$1.5M to -$1.08M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s change in accrued liabilities?
- Over 2 years (2021 to 2023), Trevi Therapeutics, Inc.'s change in accrued liabilities has grown at a -60.7% compound annual growth rate (CAGR), from $336K to $52K.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.